NCT00761852View on ClinicalTrials.gov

Signaling Mechanisms and Vascular Function in Diabetes Mellitus

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 1999

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions
Type 1 Diabetes MellitusType 2 Diabetes Mellitus
Interventions
DRUG

Ruboxistaurin

32 mg daily for 2 weeks

DRUG

Placebo

1 tab po QD for 2 weeks

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Brigham and Women's Hospital

OTHER

NCT00761852 - Signaling Mechanisms and Vascular Function in Diabetes Mellitus | Biotech Hunter | Biotech Hunter